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ABSTRACT 
To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment 
Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been 
performed. Seventeen patients (19 eyes) with serous PED associated with AMD were observed. All patients 
received 0.1ml (4mg) of intravitreal TA. The mean follow-up period was 18 months. Re-attachment of 
serous PED was observed in 37% of cases to the end of follow-up. In other cases, the height and length of 
serous PED significantly decreased. Visual acuity remained stable in all cases. No evidence of RPE tear or 
CNV development were noted. Before TA administration, intraocular pressure (IOP) was 20.18 ± 2.58 
mmHg however, after intravitreal TA, IOP increased gradually and reached its maximum of all period of 
observation (23.25±1.85mmHg) six months after injection (P=0.031). In 7 (37%) of the cases, progression to 
cataract was observed after treatment. After surgery, the visual acuity in all cases increased by 0.2 to 0.5. 
As a conclusion, intravitreal TA decreases of both the height and length of serous PED associated with AMD 
after 18 months follow-up in most cases. The presented data provides support for the hypothesis regarding 
the possibility of monotherapy of serous PED with intravitreal TA.  
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INTRODUCTION  
Serous retinal pigment epithelium detachment (PED) is one of 
the symptoms of age-related macular degeneration (AMD) and 
is detected in about 10% of patients with the exudative form of 
AMD [1-3]. Haab was the first researcher to clinically describe 
serous PED [2]. Later, through electron microscopy, it was 
confirmed that the detachment of RPE occurs between the 
inner layer of Bruch’s membrane and the basal membrane of 
RPE [4]. Its height and length fluctuates from tens of 
micrometres to several millimetres. PED is visualised in 
biomicro-ophthalmoscopy in the form of a dome-like formation 
passing into the vitreous with clear lines of yellow-gray colour. 
Shape may be various: round, oval, horseshoe-shaped. With the 
long-term existence of PED (1-3 years), visual acuity indicators 
may remain high [5]. In the natural course, PED may 
spontaneously disappear or increase, or even become 
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complicated by RPE tears (in about 10% of cases) and the 
formation of choroidal neovascularition (CNV) in about 7% of 
cases [6-8]. 
 
HYPOTHESIS  
Several authors have proven the role of increased permeability 
of the vascular wall in the pathogenesis of the exudative form 
of AMD. Triamcinolone acetonide (TA) is a long-acting 
corticosteroid, which reduces vascular permeability. Therefore, 
the use of TA increases the potency of photodynamic therapy 
and anti-vascular endothelial growth factor therapy in wet AMD 
[9-11]. Given the avascular nature of serous PED, the presence 
of inflammation elements in pathogenesis, and the increased 
effectiveness of treating PED with a combination including TA, 
the hypothesis were suggested about using a monotherapy for 
this form of AMD with intravitreal TA. 
 
METHODS 
Seventeen patients (19 eyes) with serous PED were included to 
be associated with AMD after obtaining ethical approval and 
informed consent. All of the patients received 0.1ml (4mg) of 
intravitreal TA. In the absence of positive dynamics of the 
structural parameters, re-injection was conducted 3 months 
after the previous administration of TA. As the means of 
control, data was used from the Moorfields Eye Hospital on 49 
patients (49 eyes) which involved clinical research of the laser 
photocoagulation application in treatment of serous PED 
compared to its natural course [12]. Patients underwent 
visiometry, tonometry, fluorescein angiography, and optical 
coherence tomography (OCT). OCT examined the height and 
length of serous PED. Investigations was also carried out before 
the treatment and 1, 3, 6, 12, 15, 18 months after treatment.  
Statistical analysis performed with Statistica 8.0. The 
nonparametric Mann-Whitney test used to assess the statistical 
significance of differences between indicated groups, which 
determines the level of statistical significance. 
 
RESULTS 
The average visual acuity of patients before treatment was 0.3. 
While undergoing OCT, the range of serous PED height was 115 
to 1200 microns, and the length of the serous PED was 850 to 
4660 microns.  
One month after TA administration, the visual acuity of patients 
increased to 0.35 (P = 0.43). The height of the serous PED 
decreased from 115-1200 microns to 82-1110 microns, and the 
length from 850-4660 microns to 610-3360 microns. Three 
months later, the average visual acuity was 0.3 (P = 0.27). The 
height of the serous PED was 82-1100 microns and the length 
of the serous PED was 540-3270 microns. 
On the sixth month of follow up, visual activity remained at the 
same level of 0.3 (P=0.16). The height of the serous PED 
decreased to 82-1050 microns, with the length of the serous 
PED being at the level of 628 to 3160 microns. Three patients (3 
eyes) were observed to have complete reattachment of PED 
(Fig. 1). 
Nine months later, visual acuity among the group of patients 
who had undergone TA administration was 0.29 (P=0.18). The 
height of serous PED ranged from 85 to 620 microns, and the 
length ranged from 280 to 3225 microns. The complete 
reattachment of serous PED was observed in 2 cases. Twelve 
months later, visual acuity remained unchanged, and was 0.29 
(P = 0.15). The height of serous PED was 85-620 microns, and 
the length of serous PED was 280-3225 microns. One patient (1 
eye) had complete reattachment of serous PED. Fifteen months 
later, the average visual acuity decreased to 0.27 (P = 0.13). The 
height of serous PED was 75-620 microns, and the length was 
260-3225 microns. Complete reattachment of serous PED was 
observed in one case. By the 18
th
 month, visual acuity increased 
to 0.3 (P=0.1). The height of the serous PED was from 75-600 
microns, and the length of serous PED was 260-3190 microns 
(Fig. 2, 3). 
 
 
Figure 1 Serous PED before intravitreal TA (upper). Complete 
reattachment of PED after treatment in 6 month of follow-up (Lower). 
 
In all cases of complete reattachment, the initial structural 
characteristics were different. Thus, the height of serous PED 
ranged from 225 to 1200 microns, and the length was from 935 
to 4660 microns. No connection between the size of serous 
PED, reattachment and the number of injections was reported.  
According to research carried out in the Moorfields Eye 
Hospital on 49 patients (49 eyes) whose visual acuity 
deteriorated, the size of RPE detachment preserved or 
increased over the 18 months of observation in the natural 
course of the disease [12]. 
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Figure 2. Serous PED before intravitreal TA (upper). Decreased height 
and length of serous PED after intravitreal TA in 18 months later 
(lower). 
  
Figure 3. Height of serous PED after intravitreal TA in patients with 
persisting serous PED.  
Each patient underwent 1 or 2 intravitreal injections of TA. No 
RPE re-detachment was noted. During the whole observation 
period, complete reattachment of PED was observed in 7 out of 
19 cases of intravitreal TA (Fig. 4).   
 
Figure 4. Color photo of fundus with serous PED before treatment (A). 
Angiography recirculation phase. Hyperfluorescence is observed in 
areas with serous PED (B). Colour photo of the same patient`s fundus 
after treatment (C). No hyperfluorescent area of PED in fovea has been 
noted (D). 
Prior to TA administration, the intraocular pressure (IOP) was 
20.18 ± 2.58mmHg however, after intravitreal TA, the IOP rose 
gradually and reached its maximum observation of 23.25±1.85 
mm Hg (P=0.031) six months after injection. In seven (37%) 
cases, progression of cataract was observed after treatment. In 
all cases, phacoemulsification with intraocular lens 
implantation was indicated. After surgery the visual acuity 
increased in all cases by 0.2-0.5. 
 
DISCUSSION 
The management of PED encountered various controversies. 
Thus, with the intravitreal injection of anti-VEGF to the patients 
with serous PED, a tear of RPE was observed in 17% of patients 
one month after injection. The risk of RPE tear increased by 2-5 
times after re-injection. As a result of 15-month long research 
following the photodynamic therapy carried out among 
patients with serous PED, an RPE tear was observed in 11% of 
cases [6,13,14]. 
Studies at the Moorfields Eye Hospital showed a reduction in 
visual acuity in 55% of cases (27 eyes) with the natural course 
of disease in the 9
th
 month of observation with a total 
observation period of 18 months. Visual acuity gradually 
decreased, and the size of RPE detachment either remained the 
same or increased. In 13% of cases  an RPE tear had been 
observed. 45% of cases (22 eyes) with PED who underwent 
laser photocoagulation showed a decrease in visual acuity by 
the 3
rd
 month of observation. A decrease of PED was observed 
in most cases, however visual acuity continued to decline. A 
tear after laser treatment occurred in 10% of cases [12]. 
In this context, it became an issue to develop new effective 
approaches in the treatment of age-related macular 
degeneration with PED. 
According to the literature, patients with the exudative form of 
AMD were found to have pro-inflammatory and angiogenic 
factors expressed by macrophages (TNF-α, IL-6, IL-10 and other 
cytokines), suggesting that increased vascular permeability 
plays a significant role in the pathogenesis of AMD [13,15]. 
Triamcinolone acetonide is a long-acting corticosteroid with a 
high anti-inflammatory effect which also reduces the 
permeability of the vascular wall. Also, a number of authors 
have shown that patients with wet AMD had improved results 
of CNV and PED treatment when using the combination of laser 
photocoagulation, photodynamic therapy, and anti-VEGF with 
TA [9,11]. Given the avascular nature of PED, the presence of 
inflammation elements in pathogenesis, and the increased 
effectiveness of treating PED with use of combination of TA, a 
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hypothesis were suggested regarding the possibility of 
monotherapy in this form of AMD. 
An intravitreal injection of triamcinolone acetonide provides a 
decrease of the height and length of serous PED for a period of 
18 months, and also includes its complete reattachment in 37% 
of cases. As a result of treatment, visual acuity remained stable. 
There were no complications of serous PED associated with RPE 
tear or CNV development. The intravitreal injection of TA led to 
the progression of cataracts in 37% of cases, as well as a 
transient increase of IOP, which is consistent with published 
data [14-16]. 
 
CONCLUSION  
The presented data provides support for the hypothesis about 
the possibility of using monotherapy for serous PED with 
intravitreal TA. Thus, TA acts as anti-inflammation and non-
direct anti-angiogenic factor and provides pathogenetic action 
on PED. Intravitreal injection of TA allows the complete 
reattachment of serous PED in 37% of cases, and the reduction 
of serous PED in 63% during the observation period of 18 
months. Also, it allows the retention of visual acuity compared 
to the natural course and laser treatment in serous PED. 
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